Neurological Biomarkers Market Size & Growth Report to 2030

The global neurological biomarkers market size was valued at over USD 7 billion in 2022 and estimated to register a considerable CAGR of around 13% during the forecast period from 2023 to 2030. The market is driven by increasing prevalence of neurological disorders, technological advances, personalized medicine, research and development activities, rising healthcare expenditure, supportive regulatory environment, and collaborations. The growing number of individuals affected by neurological disorders creates a demand for effective diagnostic tools. Technological advancements enable the identification and development of biomarkers, aiding in early detection and personalized treatment. Increased healthcare spending and supportive regulations further promote biomarker research. Collaborations between academic institutions, pharmaceutical companies, and research organizations facilitate the translation of findings into clinical applications.

According to the World Health Organization (WHO), epilepsy is one of the most common neurological disorders, affecting approximately 50 million people worldwide. Epilepsy accounts for about 0.6% of the global burden of disease, as measured in disability-adjusted life years (DALYs). DALYs combine the years of life lost due to premature mortality and years lived with disability. Furthermore, the WHO says, the treatment gap for epilepsy in low- and middle-income countries is estimated to be 75% or higher, meaning that a large proportion of individuals with epilepsy do not receive appropriate treatment.

Moreover, according to statistics from the World Health Organization (WHO), the global prevalence of dementia is around 50 million people, with approximately 10 million new cases reported annually. Additionally, the Alzheimer’s Association estimates that by 2050, around 13.8 million individuals aged 65 and above will be affected by Alzheimer’s dementia. In the United States, it is estimated that approximately 5.8 million people aged 65 and above were affected by Alzheimer’s dementia in 2020.

Driving Factors:

Increasing Prevalence of Neurological Disorders: The rising incidence and prevalence of neurological disorders, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and epilepsy, are driving the demand for effective diagnostic tools. Biomarkers play a crucial role in the early detection, diagnosis, and monitoring of these conditions.

Advances in Technology: Technological advancements in areas such as genomics, proteomics, neuroimaging, and bioinformatics have significantly improved our understanding of neurological disorders. These advancements have facilitated the identification and development of biomarkers that can provide valuable insights into disease mechanisms, diagnosis, and treatment response.

Growing Focus on Personalized Medicine: There is a shift towards personalized medicine, where treatments are tailored to an individual’s specific characteristics and needs. Biomarkers play a crucial role in this approach by enabling precise diagnosis, prognosis, and treatment selection based on an individual’s biomolecular profile.

Increased Research and Development Activities: The pharmaceutical and biotechnology industries, as well as academic research institutes, are investing heavily in the development of neurological biomarkers. This research and development focus aims to identify novel biomarkers that can improve disease diagnosis, enable early intervention, and monitor treatment efficacy.

Rising Healthcare Expenditure: Increased healthcare expenditure globally, particularly in developed countries, is driving the demand for advanced diagnostic tools and precision medicine approaches. The integration of biomarkers in clinical practice offers the potential for more accurate and cost-effective diagnosis and treatment.

Supportive Regulatory Environment: Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have provided guidelines and frameworks for the development and validation of biomarkers. This has fostered a supportive regulatory environment that encourages biomarker research and their translation into clinical practice.

Collaborations and Partnerships: Collaborations between academic institutions, pharmaceutical companies, diagnostic laboratories, and research organizations have led to increased investment and shared expertise in the development of neurological biomarkers. These collaborations facilitate the translation of research findings into clinically viable biomarker-based diagnostic tools.

Market Attributes:

To know more about the research study, request sample papers

Market Insights:

Global Neurological Biomarkers Market Analysis by Type

The global neurological biomarkers market is bifurcated into type, application, end-user, and geography. On the basis of type, the proteomic segment accounted for the highest revenue share of around 1/3 market share in the benchmark year This indicates that proteomic biomarkers, which involve the analysis of proteins or protein patterns in biological samples, were the dominant segment in terms of market revenue. Additionally, genomic biomarkers accounted for the second-largest market share in 2022. Genomic biomarkers hold promise in the development of personalized medicines and diagnostics, as they provide insights into an individual’s specific genetic variations and predisposition to diseases.

Genomic and proteomic biomarkers also hold significant potential in the neurological biomarkers market. Advances in genomics and proteomics have allowed researchers to identify specific genetic variations and protein expression patterns associated with neurological disorders. These biomarkers provide insights into disease mechanisms, risk assessment, and personalized treatment approaches. Metabolomic biomarkers are also gaining attention in the field. They offer valuable information about the metabolic alterations occurring in neurological disorders and can provide insights into disease progression, treatment response, and potential therapeutic targets.

Genomic Biomarkers: Genomic biomarkers involve the analysis of genetic variations, such as DNA mutations, single nucleotide polymorphisms (SNPs), or gene expression patterns. These biomarkers provide insights into an individual’s genetic predisposition to certain neurological disorders or their response to specific treatments.

Proteomic Biomarkers: Proteomic biomarkers focus on the analysis of proteins or protein patterns in biological samples, such as blood or cerebrospinal fluid. Changes in protein expression levels or post-translational modifications can indicate the presence or progression of neurological disorders.

Metabolomic Biomarkers: Metabolomic biomarkers involve the measurement and analysis of small molecules or metabolites in biological samples. They provide information about the metabolic pathways and alterations associated with neurological disorders, offering insights into disease mechanisms and treatment response.

Imaging Biomarkers: Imaging biomarkers utilize neuroimaging techniques, such as magnetic resonance imaging (MRI), positron emission tomography (PET), or computed tomography (CT) scans, to identify structural or functional changes in the brain. These biomarkers aid in the diagnosis, staging, and monitoring of neurological disorders.

Others: The “others” category may include emerging types of biomarkers that are not classified within the traditional genomic, proteomic, metabolomic, or imaging categories. These biomarkers could include epigenetic markers, microRNA signatures, or novel biomarkers under investigation.

Global Neurological Biomarkers Market Analysis by Application

On the basis of application, the global neurological biomarkers market is segmented into alzheimer’s disease, parkinson’s disease, multiple sclerosis, autism spectrum disorder, and others. the alzheimer’s disease segment dominated the global market in the benchmark year and anticipated to hold the largest revenue share of over 1/3 market share by the end of the analysis period. The growth of the segment can be attributed to the significant disease burden and the availability of clinical products, such as amyloid PET tracers for diagnostic purposes. Additionally, government and non-profit organizations are playing a crucial role by offering numerous research opportunities, which are expected to further drive market growth. Notably, collaborative initiatives like Biomarkers Across Neurodegenerative Diseases (BAND), a joint effort by the Alzheimer’s Association, The Michael J. Fox Foundation for Parkinson’s Research (MJFF), Alzheimer’s Research U.K., and the Weston Brain Institute, are providing funding for biomarker discovery, thus contributing to the advancement of research in this field.

Alzheimer’s Disease: Biomarkers used in the diagnosis, progression monitoring, and prediction of Alzheimer’s disease. These biomarkers may include proteins like amyloid beta and tau protein, genetic variations associated with the disease, or neuroimaging markers to detect structural and functional changes in the brain.

Parkinson’s Disease: Biomarkers used in the diagnosis, progression monitoring, and prediction of Parkinson’s disease. These biomarkers may involve proteins like alpha-synuclein, genetic variations associated with the disease, or neuroimaging markers to assess the dopaminergic system and detect brain changes.

Multiple Sclerosis: Biomarkers used in the diagnosis, prognosis, and treatment response monitoring of multiple sclerosis. These biomarkers may include immune system-related proteins, genetic markers associated with the disease, or neuroimaging markers to detect lesions or brain atrophy.

Autism Spectrum Disorder: Biomarkers used in the diagnosis and characterization of autism spectrum disorder. These biomarkers may involve genetic variations associated with the disorder, protein markers related to synaptic function or immune system dysregulation, or neuroimaging markers to assess brain connectivity and structure.

Others: This category may include applications of neurological biomarkers in other neurological disorders, such as epilepsy, stroke, Huntington’s disease, or traumatic brain injury. Biomarkers specific to these disorders can aid in diagnosis, prognosis, and treatment monitoring.

The neurological biomarkers market research report presents the analysis of each segment from 2020 to 2030 considering 2022 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2023 to 2030.

Historical & Forecast Period

• 2020-21 – Historical Year
• 2022 – Base Year
• 2023-2030 – Forecast Period

Market Segmentation:

By Type:

• Genomic
• Proteomic
• Metabolomic
• Imaging
• Others

By Application:

• Alzheimer’s Disease
• Parkinson’s Disease
• Multiple Sclerosis
• Autism Spectrum Disorder
• Others

By End-User:

• Hospital & Hospital Laboratories
• Independent Clinical Diagnostic Centers
• Research Organizations and Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Geographic Coverage

On the basis of region, North America is accounted to hold the largest revenue share of the global neurological biomarkers market in 2022. Several factors contribute to North America’s prominence in the market. These include a high disease burden, robust healthcare infrastructure, advanced research capabilities, and significant investments in Alzheimer’s disease research and development. The region is home to leading pharmaceutical companies, academic institutions, and research organizations dedicated to finding effective treatments and biomarkers for Alzheimer’s disease.

Additionally, North America has well-established regulatory frameworks, supportive reimbursement policies, and strong advocacy groups that drive awareness and facilitate market growth. These factors create an environment conducive to clinical trials, biomarker research, and the adoption of innovative diagnostic and treatment approaches.

Competitive Assessment

Some of the prominent market players operating in the global neurological biomarkers market are Thermo Fisher Scientific, Bio-Rad Laboratories, Siemens Healthineers, Roche Diagnostics, and Abbott Laboratories. Companies are exploring markets through expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. For instance:

• In November 2021, Eisai Co. Ltd. and Biogen Inc. shared findings from the Phase 3 AHEAD 3-45 trial of lecanemab (BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for Alzheimer’s disease. The data highlighted the use of plasma-based biomarkers in assessing the efficacy of lecanemab in clinical trials.
• In October 2021, Diadem made an announcement regarding the release of clinical data showcasing the potential of their AlzoSure biomarker test. The test demonstrated the ability to predict the progression of Alzheimer’s disease several years before the manifestation of symptoms. This could enable early intervention and better management of the disease.
• In 2021, C2N Diagnostics launched PrecivityAD, a blood-based test designed to aid in the early detection of Alzheimer’s disease. The test measures specific blood-based biomarkers, including amyloid beta and tau proteins, which are associated with Alzheimer’s pathology.
• In September 2020, Novartis Pharma AG and Siemens Healthineers entered into a cooperation agreement to develop and market diagnostic tests for Novartis’ pharmaceutical portfolio. The initial focus is on creating a serum NFL immunoassay to support Novartis’ work in multiple sclerosis and other neuroscience areas.
• In August 2020, Johnson & Johnson Services, Inc. partnered with Enigma Biomedical Group to assess the potential of novel neuroimaging biomarkers, namely JNJ-64413739 and JNJ-64511070, in gaining deeper insights into Alzheimer’s disease and other forms of dementia. This collaboration aims to advance the understanding of these debilitating conditions and potentially contribute to the development of improved diagnostic and therapeutic approaches.

Key Companies:

• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Siemens Healthineers
• Roche Diagnostics
• Abbott Laboratories
• Biogen
• Pfizer Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Eli Lilly and Company
• Novartis AG
• Quest Diagnostics

Key Questions Answered by Neurological Biomarkers Market Report

• Global neurological biomarkers market forecasts from 2023-2030
• Regional market forecasts from 2023-2030 covering Asia-Pacific, North America, Europe, Middle East & Africa, and Latin America
• Country-level forecasts from 2023-2030 covering 15 major countries from the regions as mentioned above
• Neurological biomarkers submarket forecasts from 2023-2030 covering the market by type, application, end-user, and geography
• Various industry models such as SWOT analysis, Value Chain Analysis about the market
• Analysis of the key factors driving and restraining the growth of the global, regional, and country-level neurological biomarkers markets from 2023-2030
• Competitive Landscape and market positioning of top 10 players operating in the market